

Giulio Marchesini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8333779/giulio-marchesini-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

398
papers

41,751
citations

79
h-index

199
g-index

427
ext. papers

49,613
ext. citations

6
avg, IF

7.36
L-index

#	Paper	IF	Citations
398	The Role of Psychological Well-Being in Weight Loss: New Insights from a Comprehensive Lifestyle Intervention. <i>International Journal of Clinical and Health Psychology</i> , 2022 , 22, 100279	5.1	1
397	The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2021 ,	4.0	12
396	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
395	European MAFLD Preparedness Index: Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , 2021 , 3, 100234	10.3	13
394	Incidence of diabetes mellitus in Italy in year 2018. A nationwide population-based study of the ARNO Diabetes Observatory. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 2338-2344	4.5	2
393	Non-alcoholic fatty liver disease: Not time for an obituary just yet!. <i>Journal of Hepatology</i> , 2021 , 74, 972-974	9.4	12
392	Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. <i>Liver International</i> , 2021 , 41, 731-742	7.9	4
391	Initial treatment of diabetes in Italy. A nationwide population-based study from of the ARNO Diabetes Observatory. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 2661-2668	4.5	0
390	Genes and lifestyle: Which of the two is more relevant in driving NAFLD progression?. <i>Digestive and Liver Disease</i> , 2021 , 53, 1433-1434	3.3	
389	Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 1-5	4	
388	The Effect of Neuropathy and Diabetes Type on Multisegment Foot Kinematics: A Cohort Study on 70 Participants with Diabetes. <i>Applied Sciences (Switzerland)</i> , 2021 , 11, 8848	2.6	0
387	Non-alcoholic fatty liver disease: A patient guideline. <i>JHEP Reports</i> , 2021 , 3, 100322	10.3	17
386	Management of non-alcoholic fatty liver disease. <i>BMJ, The</i> , 2021 , 372, m4747	5.9	31
385	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2021 ,	13.4	7
384	Analysis of Clinical Profiles, Deformities, and Plantar Pressure Patterns in Diabetic Foot Syndrome. <i>Applied Sciences (Switzerland)</i> , 2021 , 11, 11464	2.6	0
383	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.. <i>Gut</i> , 2021 ,	19.2	8
382	Maternal PKU: Defining phenylalanine tolerance and its variation during pregnancy, according to genetic background. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 977-983	4.5	1

381	Prevalence of orthorexic traits in type 2 diabetes mellitus: at the crossroads between nutritional counseling and eating disorders. <i>Acta Diabetologica</i> , 2020 , 57, 1117-1119	3.9	5
380	Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 1014-1022	4.5	4
379	Nurse-managed basal-bolus versus sliding-scale insulin regimen in subjects with hyperglycemia at admission for orthopedic surgery: a propensity score approach. <i>Acta Diabetologica</i> , 2020 , 57, 835-842	3.9	3
378	Fatty liver in pregnancy: a narrative review of two distinct conditions. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 127-135	4.2	8
377	Stress Hyperglycemia and Complications Following Traumatic Injuries in Individuals With/Without Diabetes: The Case of Orthopedic Surgery. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020 , 13, 9-17	3.4	8
376	Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update. <i>Current Pharmaceutical Design</i> , 2020 , 26, 1110-1118	3.3	3
375	Obesity and NAFLD: Same Problem? 2020 , 1-14		
374	Signal of potentially protective drug-drug interactions from spontaneous reporting systems: proceed with caution. <i>Acta Diabetologica</i> , 2020 , 57, 115-116	3.9	2
373	A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 1945-1953	4.5	10
372	The Effect of Liraglutide on EBlockade for Preventing Variceal Bleeding: A Case Series. <i>Annals of Internal Medicine</i> , 2020 , 173, 404-405	8	4
371	Stress Hyperglycemia and Mortality in Subjects With Diabetes and Sepsis 2020 , 2, e0152		11
370	Clinical burden of diabetes in Italy in 2018: a look at a systemic disease from the ARNO Diabetes Observatory. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	9
369	Correlations between weight-bearing 3D bone architecture and dynamic plantar pressure measurements in the diabetic foot. <i>Journal of Foot and Ankle Research</i> , 2020 , 13, 64	3.2	5
368	Motivational Interviewing Adapted to Group Setting for the Treatment of Relapse in the Behavioral Therapy of Obesity. A Clinical Audit. <i>Nutrients</i> , 2020 , 12,	6.7	1
367	Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system. <i>Acta Diabetologica</i> , 2020 , 57, 71-80	3.9	14
366	The association between weight maintenance and session-by-session diet adherence, weight loss and weight-loss satisfaction. <i>Eating and Weight Disorders</i> , 2020 , 25, 127-133	3.6	10
365	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 935-944.e3	6.9	55
364	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020 , 72, 14-24	13.4	75

363	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , 2020 , 71, 1213-1227	104
362	Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1 8
361	Prevention and Treatment of Sarcopenic Obesity in Women. <i>Nutrients</i> , 2019 , 11,	6.7 22
360	Body composition, dual-energy X-ray absorptiometry and obesity: the paradigm of fat (re)distribution. <i>BJR case Reports</i> , 2019 , 5, 20170078	0.7 2
359	Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1087-1090	4 3
358	Dysfunctional eating in type 2 diabetes mellitus: A multicenter Italian study of socio-demographic and clinical associations. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019 , 29, 983-990	4.5 4
357	Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study. <i>Endocrinology, Diabetes and Metabolism</i> , 2019 , 2, e00082	2.7 4
356	Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?. <i>Nutrients</i> , 2019 , 11,	6.7 14
355	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	40 425
354	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. <i>Transplantation</i> , 2019 , 103, 22-27	1.8 181
353	Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice. <i>Journal of Endocrinological Investigation</i> , 2019 , 42, 787-796	5.2 2
352	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2019 , 51, 190-205	3.3 36
351	Correlation between DXA and laboratory parameters in normal weight, overweight, and obese patients. <i>Nutrition</i> , 2019 , 61, 143-150	4.8 9
350	Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis. <i>Acta Diabetologica</i> , 2019 , 56, 289-299	3.9 8
349	. <i>Proceedings of the IEEE</i> , 2018 , 106, 723-737	14.3 20
348	Expected benefits and motivation to weight loss in relation to treatment outcomes in group-based cognitive-behavior therapy of obesity. <i>Eating and Weight Disorders</i> , 2018 , 23, 205-214	3.6 6
347	The Economic Burden of Insulin-Related Hypoglycemia in Adults with Diabetes: An Analysis from the Perspective of the Italian Healthcare System. <i>Diabetes Therapy</i> , 2018 , 9, 1037-1047	3.6 8
346	Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018 , 28, 533-542	4.5 45

345	DXA-assessed changes in body composition in obese women following two different weight loss programs. <i>Nutrition</i> , 2018 , 46, 13-19	4.8	7
344	Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2711-2723	6.7	16
343	Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. <i>Cardiovascular Diabetology</i> , 2018 , 17, 28	8.7	22
342	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018 , 69, 896-904	13.4	550
341	Sense of coherence, self-esteem, and health locus of control in subjects with type 1 diabetes mellitus with/without satisfactory metabolic control. <i>Journal of Endocrinological Investigation</i> , 2018 , 41, 307-314	5.2	7
340	The Effect of Lutein on Eye and Extra-Eye Health. <i>Nutrients</i> , 2018 , 10,	6.7	71
339	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. <i>Journal of Hepatology</i> , 2018 , 69, 1155-1163	13.4	25
338	Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1903-1914	4	10
337	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis 2018 , 68, 349		1
336	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017 , 49, 471-483	3.3	179
335	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. <i>Lancet, The</i> , 2017 , 389, 1399-1409	40	324
334	Acute Heart Failure in the Emergency Department: the SAFE-SIMEU Epidemiological Study. <i>Journal of Emergency Medicine</i> , 2017 , 53, 178-185	1.5	1
333	Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1594-1601	6.7	12
332	Branched-chain amino acids for people with hepatic encephalopathy. <i>The Cochrane Library</i> , 2017 , 5, CD009399	9.12	64
331	Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 510-518	6.1	111
330	Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?. <i>Digestive and Liver Disease</i> , 2017 , 49, 235-240	3.3	29
329	Long-term treatment of severe obesity: are lifestyle interventions still an option?. <i>Expert Review of Endocrinology and Metabolism</i> , 2017 , 12, 391-400	4.1	8
328	Estimating the risk of severe hypoglycemic event related to glucose-lowering treatment among Italian patients with diabetes: the HYPOTHESIS database. <i>ClinicoEconomics and Outcomes Research</i> , 2017 , 9, 711-720	1.7	2

327	Evidence-Based Medicine and the Problem of Healthy Volunteers. <i>Annals of Hepatology</i> , 2017 , 16, 832-834	4	
326	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 887-897	18.1	154
325	Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017 , 27, 1098-1107	4.5	21
324	Response to: Comment to "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". <i>Journal of Hepatology</i> , 2017 , 66, 466-467	13.4	21
323	The Influence of Weight-Loss Expectations on Weight Loss and of Weight-Loss Satisfaction on Weight Maintenance in Severe Obesity. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2017 , 117, 32-38	3.9	19
322	Supervised vs. self-selected physical activity for individuals with diabetes and obesity: the Lifestyle Gym program. <i>Internal and Emergency Medicine</i> , 2017 , 12, 45-52	3.7	8
321	Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 877-89	6.1	54
320	Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction. <i>Digestive Diseases</i> , 2016 , 34 Suppl 1, 3-10	3.2	19
319	Are severe hypoglycemic episodes in diabetes correctly identified by administrative data? Evidence of underreporting from the HYPOTHESIS study. <i>Acta Diabetologica</i> , 2016 , 53, 677-80	3.9	7
318	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 323-34	59.2	1956
317	Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. <i>Hepatology</i> , 2016 , 63, 2032-43	11.2	183
316	Impaired Lipid Profile is a Risk Factor for the Development of Sexual Dysfunction in Women. <i>Journal of Sexual Medicine</i> , 2016 , 13, 46-54	1.1	8
315	Acute heart failure in the emergency department: a follow-up study. <i>Internal and Emergency Medicine</i> , 2016 , 11, 115-22	3.7	4
314	NAFLD: A glance at the landscape of pharmacological treatment. <i>Annals of Hepatology</i> , 2016 , 15, 673-81	3.1	18
313	Long-term weight loss maintenance for obesity: a multidisciplinary approach. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2016 , 9, 37-46	3.4	116
312	The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2016 , 95, e3446	1.8	25
311	How Much Fat Does One Need to Eat to Get a Fatty Liver? A Dietary View of NAFLD 2016 , 109-122		1
310	The relative burden of diabetes complications on healthcare costs: The population-based CINECA-SID ARNO Diabetes Observatory. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016 , 26, 944-50	4.5	35

309	Response to letter to the editor: Gallo F et al., "The economic burden of severe hypoglycemia: Two sides of the same coin" <i>Nutr Metab Cardiovasc Dis.</i> 2016;26:850-851. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016 , 26, 851-2	4.5	
308	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016 , 64, 1388-402	13.4	2065
307	Costs associated with emergency care and hospitalization for severe hypoglycemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016 , 26, 345-51	4.5	36
306	EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. <i>Obesity Facts</i> , 2016 , 9, 65-90	5.1	197
305	Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016 , 26, 380-6	4.5	25
304	Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?. <i>Diabetes and Metabolism</i> , 2016 , 42, 142-56	5.4	59
303	NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders. <i>Current Hepatology Reports</i> , 2016 , 15, 103-112	1	2
302	Incidence, prevalence, costs and quality of care of type 1 diabetes in Italy, age 0-29 years: The population-based CINECA-SID ARNO Observatory, 2002-2012. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016 , 26, 1104-1111	4.5	11
301	Switching among Equivalents in Chronic Cardiovascular Therapies: Real World Data from Italy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016 , 118, 63-9	3.1	1
300	The hepatic expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 193-200	5.6	21
299	Visceral fat and body composition changes in a female population after RYGBP: a two-year follow-up by DXA. <i>Obesity Surgery</i> , 2015 , 25, 443-51	3.7	42
298	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015 , 373, 2117-28	59.2	6064
297	Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. <i>Digestive and Liver Disease</i> , 2015 , 47, 181-90	3.3	430
296	Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. <i>Journal of Hepatology</i> , 2015 , 62, 928-33	13.4	115
295	Obesity in the Context of Aging: Quality of Life Considerations. <i>Pharmacoeconomics</i> , 2015 , 33, 655-72	4.4	23
294	Branched-chain amino acids for people with hepatic encephalopathy. <i>Cochrane Database of Systematic Reviews</i> , 2015 , CD001939		22
293	Weight Loss Expectations and Attrition in Treatment-Seeking Obese Women. <i>Obesity Facts</i> , 2015 , 8, 311-8	5.1	26
292	Branched-chain amino acids for people with hepatic encephalopathy. <i>Cochrane Database of Systematic Reviews</i> , 2015 , CD001939		32

291	Personality, attrition and weight loss in treatment seeking women with obesity. <i>Clinical Obesity</i> , 2015 , 5, 266-72	3.6	8
290	Evidence of a diurnal thermogenic handicap in obesity. <i>Chronobiology International</i> , 2015 , 32, 299-302	3.6	14
289	ICD Code Retrieval: Novel Approach for Assisted Disease Classification. <i>Lecture Notes in Computer Science</i> , 2015 , 147-161	0.9	6
288	Personality Traits in Obesity Associated with Binge Eating and/or Night Eating. <i>Current Obesity Reports</i> , 2014 , 3, 120-6	8.4	6
287	The influence of cognitive factors in the treatment of obesity: Lessons from the QUOVADIS study. <i>Behaviour Research and Therapy</i> , 2014 , 63, 157-61	5.2	28
286	A standard ballroom and Latin dance program to improve fitness and adherence to physical activity in individuals with type 2 diabetes and in obesity. <i>Diabetology and Metabolic Syndrome</i> , 2014 , 6, 74	5.6	22
285	Liver in the analysis of body composition by dual-energy X-ray absorptiometry. <i>British Journal of Radiology</i> , 2014 , 87, 20140232	3.4	6
284	Reply to: "is industrial fructose just a marker of an unhealthy dietary pattern?". <i>Journal of Hepatology</i> , 2014 , 61, 173-5	13.4	
283	Risk of malnutrition (over and under-nutrition): validation of the JaNuS screening tool. <i>Clinical Nutrition</i> , 2014 , 33, 1087-94	5.9	8
282	Under-treatment of migrants with diabetes in a universalistic health care system: the ARNO Observatory. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014 , 24, 393-9	4.5	21
281	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. <i>Atherosclerosis</i> , 2014 , 232, 99-109	3.1	97
280	The management of severe hypoglycemia by the emergency system: the HYPOTHESIS study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014 , 24, 1181-8	4.5	24
279	Physical activity support or weight loss counseling for nonalcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2014 , 20, 10128-36	5.6	19
278	Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014 , 24, 1346-53	4.5	34
277	Sexuality and psychopathological aspects in premenopausal women with metabolic syndrome. <i>Journal of Sexual Medicine</i> , 2014 , 11, 2020-8	1.1	17
276	Reply to: "Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients". <i>Journal of Hepatology</i> , 2014 , 60, 677-8	13.4	1
275	A 360-degree overview of body composition in healthy people: relationships among anthropometry, ultrasonography, and dual-energy x-ray absorptiometry. <i>Nutrition</i> , 2014 , 30, 696-701	4.8	40
274	The role of medications for the management of patients with NAFLD. <i>Clinics in Liver Disease</i> , 2014 , 18, 73-89	4.6	24

273	Stage of change and motivation to healthy diet and habitual physical activity in type 2 diabetes. <i>Acta Diabetologica</i> , 2014 , 51, 559-66	3.9	24
272	Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2014 , 9, e87523	3.7	83
271	Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?. <i>Metabolic Brain Disease</i> , 2013 , 28, 221-5	3.9	66
270	Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH. <i>Hepatology International</i> , 2013 , 7 Suppl 2, 814-22	8.8	4
269	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2013 , 59, 1169-76	13.4	28
268	The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. <i>Acta Diabetologica</i> , 2013 , 50, 569-77	3.9	79
267	A psychological support program for individuals with Type 1 diabetes. <i>Acta Diabetologica</i> , 2013 , 50, 209-16	3.6	13
266	Personality features of obese women in relation to binge eating and night eating. <i>Psychiatry Research</i> , 2013 , 207, 86-91	9.9	22
265	Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2013 , 58, 771-7	13.4	52
264	Emotionally focused group therapy and dietary counseling in binge eating disorder. Effect on eating disorder psychopathology and quality of life. <i>Appetite</i> , 2013 , 71, 361-8	4.5	11
263	Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. <i>Journal of Nutrition</i> , 2013 , 143, 1263-8	4.1	69
262	Health and ageing: a cross-sectional study of body composition. <i>Clinical Nutrition</i> , 2013 , 32, 569-78	5.9	46
261	Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 392-400	6.1	126
260	High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 174-82	3.4	10
259	Physical activity for the prevention and treatment of metabolic disorders. <i>Internal and Emergency Medicine</i> , 2013 , 8, 655-66	3.7	25
258	Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β -cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 2100-5	5.6	76
257	Longstanding underweight eating disorder: associated features and treatment outcome. <i>Psychotherapy Research</i> , 2013 , 23, 315-23	3.6	11
256	Preliminary study about the possible glycemic clinical advantage in using a fixed combination of <i>Berberis aristata</i> and <i>Silybum marianum</i> standardized extracts versus only <i>Berberis aristata</i> in patients with type 2 diabetes. <i>Clinical Pharmacology: Advances and Applications</i> , 2013 , 5, 167-74	1.5	28

255	Emotion-focused therapy and dietary counseling for obese patients with binge eating disorder: a propensity score-adjusted study. <i>Psychotherapy and Psychosomatics</i> , 2013 , 82, 193-4	9.4	14
254	Gender difference in hepatic steatosis index and lipid accumulation product ability to predict incident metabolic syndrome in the historical cohort of the Brisighella Heart Study. <i>Metabolic Syndrome and Related Disorders</i> , 2013 , 11, 412-6	2.6	20
253	A randomized trial of energy-restricted high-protein versus high-carbohydrate, low-fat diet in morbid obesity. <i>Obesity</i> , 2013 , 21, 1774-81	8	20
252	Antiplatelet therapy and the outcome of subjects with intracranial injury: the Italian SIMEU study. <i>Critical Care</i> , 2013 , 17, R53	10.8	51
251	Major factors for facilitating change in behavioral strategies to reduce obesity. <i>Psychology Research and Behavior Management</i> , 2013 , 6, 101-10	3.8	48
250	Dietary Factors in the Pathogenesis and Care of Patients with Fatty Liver Disease 2013 , 248-259		
249	PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2013 , 8, e74089	3.7	47
248	Prevalence of sexual dysfunction among postmenopausal women with and without metabolic syndrome. <i>Journal of Sexual Medicine</i> , 2012 , 9, 434-41	1.1	46
247	Objective and subjective binge eating in underweight eating disorders: associated features and treatment outcome. <i>International Journal of Eating Disorders</i> , 2012 , 45, 370-6	6.3	14
246	A controlled, class-based multicomponent intervention to promote healthy lifestyle and to reduce the burden of childhood obesity. <i>Pediatric Obesity</i> , 2012 , 7, 436-45	4.6	20
245	Hepatic encephalopathy and health-related quality of life. <i>Clinics in Liver Disease</i> , 2012 , 16, 159-70	4.6	24
244	Author's reply: Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 289-290	4	
243	Impatto delle incretine sulla gestione del paziente diabetico: dati del monitoraggio antidiabetici AIFA. <i>L'Endocrinologo</i> , 2012 , 13, 210-215	0	
242	Predicting unfavorable outcome in subjects with diagnosis of chest pain of undifferentiated origin. <i>American Journal of Emergency Medicine</i> , 2012 , 30, 61-7	2.9	2
241	Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. <i>Drug Safety</i> , 2012 , 35, 315-23	5.1	29
240	Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance. <i>Diabetes Care</i> , 2012 , 35, 2607-12	14.6	34
239	Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2012 , 5, 213-7	3.4	60
238	Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. <i>Hepatology</i> , 2012 , 55, 1317-23	11.2	105

237	Diabetes and hepatocellular cancer risk: not only a matter of hyperglycemia. <i>Hepatology</i> , 2012 , 55, 1298-300	14.6	17
236	Quality of diabetes care in Italy: information from a large population-based multiregional observatory (ARNO diabetes). <i>Diabetes Care</i> , 2012 , 35, e64	14.6	14
235	Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2012 , 7, e41183	3.7	38
234	Anthropometry and Nutritional Rehabilitation in Underweight Eating Disorders 2012 , 2807-2820		
233	Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2011 , 43, 73-7	3.3	14
232	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , 2011 , 43, 404-10	3.3	24
231	Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. <i>Journal of Hepatology</i> , 2011 , 54, 1244-9	13.4	82
230	The direct economic cost of pharmacologically-treated diabetes in Italy-2006. The ARNO observatory. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011 , 21, 339-46	4.5	33
229	Metabolic syndrome in subjects at high risk for type 2 diabetes: the genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011 , 21, 699-705	4.5	13
228	Cognitive-behavioral strategies to increase the adherence to exercise in the management of obesity. <i>Journal of Obesity</i> , 2011 , 2011, 348293	3.7	133
227	TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. <i>Journal of Viral Hepatitis</i> , 2011 , 18, e372-80	3.4	17
226	Cognitive-behavioral treatment of nonalcoholic Fatty liver disease: a propensity score-adjusted observational study. <i>Obesity</i> , 2011 , 19, 763-70	8	33
225	Effects of cognitive-behavioral treatment for weight loss in family members. <i>Journal of the American Dietetic Association</i> , 2011 , 111, 1712-9		18
224	HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. <i>Acta Diabetologica</i> , 2011 , 48, 337-343	3.9	20
223	Massive weight loss without surgery in a super obese patient. <i>Obesity Surgery</i> , 2011 , 21, 540-5	3.7	2
222	Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2657-72	4	19
221	Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. <i>Diabetes Care</i> , 2011 , 34, 1369-71	14.6	184
220	Therapeutic hypothermia after cardiac arrest: the Mediterranean-diet Italian style. <i>Resuscitation</i> , 2011 , 82, 637-8	4	1

219	Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2011 , 16, 121-36	3.7	15
218	Analysis of different decision aids for clinical use in pediatric head injury in an emergency department of a general hospital. <i>Journal of Trauma</i> , 2011 , 70, E79-83		5
217	Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011 , 104, 141-9	2.7	49
216	Commentary: Liver enzymes and the risk of adverse cardiovascular outcomes--the lower, the better?. <i>International Journal of Epidemiology</i> , 2011 , 40, 1539-41	7.8	8
215	Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. <i>Gut</i> , 2011 , 60, 108-15	19.2	22
214	Night eating syndrome and weight loss outcome in obese patients. <i>International Journal of Eating Disorders</i> , 2011 , 44, 150-6	6.3	20
213	Behavioral Aspects of Nonalcoholic Fatty Liver Disease: Diet, Causes, and Treatment 2011 , 1833-1844		
212	Symptoms of Starvation in Eating Disorder Patients 2011 , 2259-2269		6
211	Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010 , Volume 3, 373-385	3.4	38
210	Predicting intracranial lesions by antiplatelet agents in subjects with mild head injury. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 1275-9	5.5	33
209	Double heterozygous mutations involving both HNF1A/MODY3 and HNF4A/MODY1 genes: a case report. <i>Diabetes Care</i> , 2010 , 33, 2336-8	14.6	19
208	Metabolic syndrome: relevant for all types of chronic liver diseases?. <i>Gut</i> , 2010 , 59, 1314-5	19.2	1
207	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2010 , 59, 267-73	19.2	117
206	The effect of lifestyle changes in non-alcoholic fatty liver disease. <i>Digestive Diseases</i> , 2010 , 28, 267-73	3.2	46
205	Insulin resistance in nonalcoholic fatty liver disease. <i>Current Pharmaceutical Design</i> , 2010 , 16, 1941-51	3.3	238
204	Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. <i>Digestive and Liver Disease</i> , 2010 , 42, 272-82	3.3	159
203	Prevention and treatment of nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2010 , 42, 331-40	3.3	15
202	HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Gastroenterology</i> , 2010 , 138, 905-12	13.3	203

201	Weight management, psychological distress and binge eating in obesity. A reappraisal of the problem. <i>Appetite</i> , 2010 , 54, 269-73	4.5	30
200	Metabolic syndrome and insulin resistance in subjects with morbid obesity. <i>Obesity Surgery</i> , 2010 , 20, 295-301	3.7	28
199	Effects of cognitive-behavioral therapy on Eating Disorders: neurotransmitter secretory response to treatment. <i>Psychoneuroendocrinology</i> , 2010 , 35, 729-37	5	9
198	The changing face of mild head injury: temporal trends and patterns in adolescents and adults from 1997 to 2008. <i>Injury</i> , 2010 , 41, 913-7	2.5	13
197	Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2010 , 51, 1158-67	11.2	318
196	Clinical and psychological correlates of health-related quality of life in obese patients. <i>Health and Quality of Life Outcomes</i> , 2010 , 8, 90	3	57
195	Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010 , 3, 373-85	3.4	38
194	Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis. <i>World Journal of Gastroenterology</i> , 2010 , 16, 348-53	5.6	26
193	ESPEN Guidelines on Parenteral Nutrition: hepatology. <i>Clinical Nutrition</i> , 2009 , 28, 436-44	5.9	169
192	Psychological variables associated with weight loss in obese patients seeking treatment at medical centers. <i>Journal of the American Dietetic Association</i> , 2009 , 109, 2010-6		59
191	Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. <i>Hepatology</i> , 2009 , 49, 195-203	11.2	56
190	Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. <i>Hepatology</i> , 2009 , 50, 697-706	11.2	117
189	Predictors of health-related quality of life in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 30, 469-76	6.1	114
188	Night eating syndrome in class II-III obesity: metabolic and psychopathological features. <i>International Journal of Obesity</i> , 2009 , 33, 899-904	5.5	42
187	Self-induced vomiting in eating disorders: Associated features and treatment outcome. <i>Behaviour Research and Therapy</i> , 2009 , 47, 680-4	5.2	20
186	Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study. <i>Fertility and Sterility</i> , 2009 , 91, 2537-44	4.8	32
185	Are behavioural approaches feasible and effective in the treatment of type 2 diabetes? A propensity score analysis vs. prescriptive diet. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009 , 19, 313-20	4.5	15
184	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. <i>Antiviral Therapy</i> , 2009 , 14, 631-639	1.6	18

183	Metabolic syndrome, psychological status and quality of life in obesity: the QUOVADIS Study. <i>International Journal of Obesity</i> , 2008 , 32, 185-91	5.5	58
182	Metabolic syndrome and health-related quality of life: does psychological well-being matter?. <i>Annals of Epidemiology</i> , 2008 , 18, 592-3	6.4	3
181	Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008 , 18, 624-31	4.5	59
180	Personality dimensions and treatment drop-outs among eating disorder patients treated with cognitive behavior therapy. <i>Psychiatry Research</i> , 2008 , 158, 381-8	9.9	15
179	Is amenorrhea a clinically useful criterion for the diagnosis of anorexia nervosa?. <i>Behaviour Research and Therapy</i> , 2008 , 46, 1290-4	5.2	32
178	Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. <i>Clinical Therapeutics</i> , 2008 , 30, 1168-76	3.5	97
177	Compulsive exercise to control shape or weight in eating disorders: prevalence, associated features, and treatment outcome. <i>Comprehensive Psychiatry</i> , 2008 , 49, 346-52	7.3	229
176	Nutritional treatment of chronic liver failure. <i>Hepatology Research</i> , 2008 , 38 Suppl 1, S93-S101	5.1	15
175	Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. <i>Journal of Endocrinological Investigation</i> , 2008 , 31, 146-52	5.2	43
174	Vascular risk in young women with polycystic ovary and polycystic ovary syndrome. <i>Obstetrics and Gynecology</i> , 2008 , 111, 385-95	4.9	40
173	Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1136-44	0.7	149
172	Hepatotoxicity of fast food?. <i>Gut</i> , 2008 , 57, 568-70	19.2	18
171	Obesity-associated liver disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, S74-80	5.6	199
170	Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. <i>Hepatology</i> , 2008 , 47, 746-54	11.2	167
169	Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. <i>Diabetologia</i> , 2008 , 51, 1947-53	10.3	342
168	Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. <i>Liver Transplantation</i> , 2008 , 14, 1648-54	4.5	197
167	Underweight eating disorder without over-evaluation of shape and weight: Atypical anorexia nervosa?. <i>International Journal of Eating Disorders</i> , 2008 , 41, 705-12	6.3	42
166	Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. <i>Hepatology</i> , 2008 , 48, 28-37	11.2	49

165	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. <i>Hepatology</i> , 2008 , 48, 792-8	11.2	481
164	Which treatment for nonalcoholic fatty liver disease?. <i>Mini-Reviews in Medicinal Chemistry</i> , 2008 , 8, 767-752	3.5	9
163	Steatosi epatica non alcolica: un aspetto emergente della sindrome metabolica. <i>L Endocrinologo</i> , 2007 , 8, 136-143	0	
162	Metabolic syndrome and NASH. <i>Clinics in Liver Disease</i> , 2007 , 11, 105-17, ix	4.6	99
161	Essential hypertension and chronic viral hepatitis. <i>Digestive and Liver Disease</i> , 2007 , 39, 466-72	3.3	2
160	The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. <i>Hepatology</i> , 2007 , 45, 846-54	11.2	1757
159	The effect of obesity management on body image in patients seeking treatment at medical centers. <i>Obesity</i> , 2007 , 15, 2320-7	8	32
158	Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. <i>British Journal of Clinical Pharmacology</i> , 2007 , 63, 346-55	3.8	28
157	The treatment of hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2007 , 22, 389-405	3.9	50
156	NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. <i>Current Diabetes Reports</i> , 2007 , 7, 175-80	5.6	46
155	Psychological distress in morbid obesity in relation to weight history. <i>Obesity Surgery</i> , 2007 , 17, 391-9	3.7	44
154	Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. <i>Diabetes Care</i> , 2007 , 30, 2638-40	14.6	98
153	Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1251-8	0.7	234
152	Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. <i>Gut</i> , 2007 , 56, 1296-301	19.2	56
151	Correspondence between the International Diabetes Federation criteria for metabolic syndrome and insulin resistance in a cohort of Italian nondiabetic Caucasians: the GISIR database. <i>Diabetes Care</i> , 2007 , 30, e33	14.6	3
150	Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007 , 17, 493-8	4.5	14
149	Diabetes and liver disease: an ominous association. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007 , 17, 63-70	4.5	92
148	Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007 , 17, 684-98	4.5	56

147	The effect of inpatient cognitive-behavioral therapy for eating disorders on temperament and character. <i>Behaviour Research and Therapy</i> , 2007 , 45, 1335-44	5.2	30
146	Effects of Physical Exercise on the Quality of Life of Individuals with Diabetes and Obesity 2007 , 191-201		
145	Outcome research in obesity: lessons from the QUOVADIS study. <i>Drug Development Research</i> , 2006 , 67, 260-270	5.1	1
144	Reply:. <i>Hepatology</i> , 2006 , 43, 1168-1169	11.2	16
143	Gender, fatty liver and GGT. <i>Hepatology</i> , 2006 , 44, 278-9	11.2	38
142	Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. <i>Hepatology</i> , 2006 , 44, 1648-55	11.2	126
141	A physical activity program to reinforce weight maintenance following a behavior program in overweight/obese subjects. <i>International Journal of Obesity</i> , 2006 , 30, 697-703	5.5	26
140	Complexity of attrition in the treatment of obesity: clues from a structured telephone interview. <i>International Journal of Obesity</i> , 2006 , 30, 1132-7	5.5	78
139	Disease management of the metabolic syndrome in a community: study design and process analysis on baseline data. <i>Metabolic Syndrome and Related Disorders</i> , 2006 , 4, 7-16	2.6	8
138	An empowerment-based educational program improves psychological well-being and health-related quality of life in Type 1 diabetes. <i>Journal of Endocrinological Investigation</i> , 2006 , 29, 405-12	5.2	24
137	Construct validity of the Short Form-36 Health Survey and its relationship with BMI in obese outpatients. <i>Obesity</i> , 2006 , 14, 1429-37	8	38
136	Monitoring intervention programmes for out-of-hospital cardiac arrest in a mixed urban and rural setting. <i>Resuscitation</i> , 2006 , 71, 180-7	4	21
135	Non-alcoholic fatty liver disease (NAFLD)--a novel common aspect of the metabolic syndrome. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2006 , 150, 101-4	1.7	17
134	Is liver disease a threat to patients with metabolic disorders?. <i>Annals of Medicine</i> , 2005 , 37, 333-46	1.5	22
133	Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. <i>Journal of Endocrinological Investigation</i> , 2005 , 28, 333-9	5.2	112
132	Diabetes prevention strategy in offspring of type 2 diabetic patients with a direct involvement of the diseased parents. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2005 , 15, 237-8	4.5	4
131	Psychological status and depression in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2005 , 37, 593-600	3.3	119
130	A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. <i>American Journal of Gastroenterology</i> , 2005 , 100, 1082-90	0.7	516

129	Eating behavior affects quality of life in type 2 diabetes mellitus. <i>Eating and Weight Disorders</i> , 2005 , 10, 251-7	3.6	13
128	Nonalcoholic fatty liver disease and the metabolic syndrome. <i>Current Opinion in Lipidology</i> , 2005 , 16, 421-7	4.4	240
127	Branched-chain amino acid supplementation in patients with liver diseases. <i>Journal of Nutrition</i> , 2005 , 135, 1596S-601S	4.1	52
126	Update on branched-chain amino acid supplementation in liver diseases. <i>Current Opinion in Gastroenterology</i> , 2005 , 21, 197-200	3	29
125	Update on nutritional supplementation with branched-chain amino acids. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2005 , 8, 83-7	3.8	30
124	A positive blood alcohol concentration is the main predictor of recurrent motor vehicle crash. <i>Annals of Emergency Medicine</i> , 2005 , 46, 161-7	2.1	22
123	Continuous care in the treatment of obesity: an observational multicentre study. <i>Journal of Internal Medicine</i> , 2005 , 258, 265-73	10.8	59
122	Weight loss expectations in obese patients and treatment attrition: an observational multicenter study. <i>Obesity</i> , 2005 , 13, 1961-9		208
121	Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. <i>Hepatology</i> , 2005 , 42, 44-52	11.2	944
120	Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2005 , 42, 473-80	11.2	469
119	Insulin resistance: a metabolic pathway to chronic liver disease. <i>Hepatology</i> , 2005 , 42, 987-1000	11.2	601
118	Clinical performance of NICE recommendations versus NCWFNS proposal in patients with mild head injury. <i>Journal of Neurotrauma</i> , 2005 , 22, 1419-27	5.4	40
117	Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 3498-504	5.6	322
116	A combined HPLC-immunoenzymatic comprehensive screening for suspected drug poisoning in the emergency department. <i>Emergency Medicine Journal</i> , 2004 , 21, 317-22	1.5	6
115	WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2004 , 21, 383-7	3.5	95
114	Nutritional therapy in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004 , 19, S401-S405		
113	Hepatic steatosis in obese patients: clinical aspects and prognostic significance. <i>Obesity Reviews</i> , 2004 , 5, 27-42	10.6	224
112	Weight cycling in treatment-seeking obese persons: data from the QUOVADIS study. <i>International Journal of Obesity</i> , 2004 , 28, 1456-62	5.5	45

111	Weight loss expectations in obese patients seeking treatment at medical centers. <i>Obesity</i> , 2004 , 12, 2005-12	57
110	Health-related quality of life in patients with thyroid disorders. <i>Quality of Life Research</i> , 2004 , 13, 45-54	3.7 101
109	Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. <i>Hepatology</i> , 2004 , 39, 179-87	11.2 342
108	Uric acid levels and liver fibrosis in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2004 , 39, 1749-1749	11.2 5
107	Snoring, hypertension and Type 2 diabetes in obesity. Protection by physical activity. <i>Journal of Endocrinological Investigation</i> , 2004 , 27, 150-7	5.2 19
106	Plasma ghrelin concentrations, food intake, and anorexia in liver failure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2136-41	5.6 52
105	Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?. <i>Digestive and Liver Disease</i> , 2004 , 36, 165-73	3.3 66
104	Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. <i>Digestive and Liver Disease</i> , 2004 , 36, 406-11	3.3 36
103	Non-alcoholic steatohepatitis in patients cared in metabolic units. <i>Diabetes Research and Clinical Practice</i> , 2004 , 63, 143-51	7.4 18
102	The metabolic syndrome in treatment-seeking obese persons. <i>Metabolism: Clinical and Experimental</i> , 2004 , 53, 435-40	12.7 46
101	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2004 , 18, 1105-1116	2.5 32
100	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2004 , 18, 1105-16	2.5 26
99	Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5674-9	5.6 44
98	Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. <i>Hepatology</i> , 2003 , 37, 917-23	11.2 1891
97	Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. <i>Gastroenterology</i> , 2003 , 124, 1792-801	13.3 457
96	Impaired insulin-mediated amino acid plasma disappearance in non-alcoholic fatty liver disease: a feature of insulin resistance. <i>Digestive and Liver Disease</i> , 2003 , 35, 722-7	3.3 11
95	Reduced quality of life of patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2003 , 35, 46-54	3.3 37
94	Type 2 diabetes and the Naaman syndrome. <i>Diabetes Care</i> , 2003 , 26, 3195	14.6 5

93	Homocysteine and psychological traits: a study in obesity. <i>Nutrition</i> , 2002 , 18, 403-7	4.8	15
92	Effects of cognitive-behavioural therapy on health-related quality of life in obese subjects with and without binge eating disorder. <i>International Journal of Obesity</i> , 2002 , 26, 1261-7	5.5	37
91	Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. <i>Gastroenterology</i> , 2002 , 123, 134-40	13.3	1170
90	Effects of long-term oral misoprostol administration on hepatic amino acid-nitrogen metabolism in patients with cirrhosis. <i>Journal of Hepatology</i> , 2002 , 37, 15-21	13.4	1
89	Blood alcohol concentration and management of road trauma patients in the emergency department. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001 , 50, 521-8	9.4	45
88	Clinical features and natural history of nonalcoholic steatosis syndromes. <i>Seminars in Liver Disease</i> , 2001 , 21, 17-26	7.3	418
87	Factors associated with poor health-related quality of life of patients with cirrhosis. <i>Gastroenterology</i> , 2001 , 120, 170-8	13.3	362
86	Liver inflammatory cells, apoptosis, regeneration and stellate cell activation in non-alcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , 2001 , 33, 768-77	3.3	16
85	Systemic prostaglandin E1 infusion and hepatic aminonitrogen to urea nitrogen conversion in patients with type 2 diabetes in poor metabolic control. <i>Metabolism: Clinical and Experimental</i> , 2001 , 50, 253-8	12.7	1
84	Metformin in non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2001 , 358, 893-4	4.0	549
83	Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. <i>Diabetes</i> , 2001 , 50, 1844-50	0.9	1821
82	Acquired hepatocerebral degeneration: full recovery after liver transplantation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001 , 70, 136-7	5.5	39
81	Nutritional effects of oral zinc supplementation in cirrhosis. <i>Nutrition Research</i> , 2000 , 20, 1079-1089	4	23
80	Synthesis of glutathione in response to methionine load in control subjects and in patients with cirrhosis. <i>Metabolism: Clinical and Experimental</i> , 2000 , 49, 1434-9	12.7	22
79	Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment. <i>Digestive and Liver Disease</i> , 2000 , 32, 398-405	3.3	38
78	Total and functional hepatic blood flow decrease in parallel with ageing. <i>Age and Ageing</i> , 1999 , 28, 29-33		111
77	Prostaglandin E1 infusion and functional hepatic flow in control subjects and in patients with cirrhosis. <i>Digestive Diseases and Sciences</i> , 1999 , 44, 377-84	4	7
76	Cardiovascular disease in cirrhosis A point-prevalence study in relation to glucose tolerance. <i>American Journal of Gastroenterology</i> , 1999 , 94, 655-662	0.7	52

75	Association of nonalcoholic fatty liver disease with insulin resistance. <i>American Journal of Medicine</i> , 1999 , 107, 450-5	2.4	1214
74	Effects of systemic prostaglandin E1 on splanchnic and peripheral haemodynamics in control subjects and in patients with cirrhosis. <i>Prostaglandins and Other Lipid Mediators</i> , 1998 , 55, 209-18	3.7	4
73	Effects of systemic prostaglandin E1 on hepatic amino acid-nitrogen metabolism in patients with cirrhosis. <i>Hepatology</i> , 1998 , 27, 815-21	11.2	8
72	Zinc supplementation improves glucose disposal in patients with cirrhosis. <i>Metabolism: Clinical and Experimental</i> , 1998 , 47, 792-8	12.7	51
71	Quantification of gluconeogenesis in cirrhosis: response to glucagon. <i>Gastroenterology</i> , 1998 , 115, 1530-40	13.3	46
70	Gender-dependent alterations in serum leptin in alcoholic cirrhosis. <i>Gastroenterology</i> , 1998 , 115, 947-53	13.3	134
69	LONG-TERM MANAGEMENT OF ALCOHOLIC LIVER DISEASE. <i>Clinics in Liver Disease</i> , 1998 , 2, 821-838	4.6	2
68	Uncertainty in liver function assessment on the basis of single-point galactose concentration. <i>Digestion</i> , 1997 , 58, 379-83	3.6	9
67	Glutathione kinetics in normal man and in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 1997 , 26, 606-13	13.4	39
66	Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. <i>Journal of Parenteral and Enteral Nutrition</i> , 1996 , 20, 159-64	4.2	54
65	Transamination of methionine after loading in patients with cirrhosis. <i>Journal of Hepatology</i> , 1996 , 24, 95-100	13.4	8
64	Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. A prospective multicenter Italian study. AISF Group for the Study of Liver Transplantation. Associazione Italiana per lo Studio del Fegato. <i>Journal of Hepatology</i> , 1996 , 25, 474-80	13.4	43
63	Transdermal nitroglycerin in cirrhosis. A 24-hour echo-Doppler study of splanchnic hemodynamics. <i>Journal of Hepatology</i> , 1996 , 25, 498-503	13.4	9
62	The course of galactose elimination capacity in patients with alcoholic cirrhosis: possible use as a surrogate marker for death. <i>Hepatology</i> , 1996 , 24, 820-3	11.2	19
61	Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. <i>Hepatology</i> , 1996 , 23, 1084-92	11.2	49
60	Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis. <i>Hepatology</i> , 1996 , 24, 1047-52	11.2	21
59	Thyroid volume in type 1 diabetes patients without overt thyroid disease. <i>Acta Diabetologica</i> , 1995 , 32, 49-52	3.9	9
58	Effects of beta-blockade on hepatic conversion of amino acid nitrogen and on urea synthesis in cirrhosis. <i>Metabolism: Clinical and Experimental</i> , 1995 , 44, 899-905	12.7	

57	Functional hepatic flow and Doppler-assessed total hepatic flow in control subjects and in patients with cirrhosis. <i>Journal of Hepatology</i> , 1995 , 23, 129-34	13.4	57
56	Reduced ubiquinone plasma levels in patients with liver cirrhosis and in chronic alcoholics. <i>Liver</i> , 1994 , 14, 138-40		12
55	Kinetics of hepatic amino-nitrogen conversion in ageing man. <i>Liver</i> , 1994 , 14, 288-94		19
54	Prognostic significance of diabetes in patients with cirrhosis. <i>Hepatology</i> , 1994 , 20, 119-125	11.2	146
53	Vegetable and animal protein diets. <i>Journal of Internal Medicine</i> , 1994 , 236, 102-103	10.8	
52	Hepatic conversion of amino-nitrogen to urea in thyroid diseases. II. A study in hyperthyroid patients. <i>Metabolism: Clinical and Experimental</i> , 1994 , 43, 1023-9	12.7	6
51	Prognostic significance of diabetes in patients with cirrhosis. <i>Hepatology</i> , 1994 , 20, 119-25	11.2	148
50	Model-derived assessment of urea appearance in response to alanine infusion: a quantitative measure of liver function in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993 , 8, 550-6	4	
49	Prognostic significance of portal hemodynamics in patients with compensated cirrhosis. <i>Journal of Hepatology</i> , 1993 , 17, 56-61	13.4	71
48	Unresponsiveness of hepatic nitrogen metabolism to glucagon infusion in patients with cirrhosis: Dependence on liver cell failure. <i>Hepatology</i> , 1993 , 18, 28-35	11.2	16
47	Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. <i>Journal of Internal Medicine</i> , 1993 , 233, 385-92	10.8	110
46	Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. <i>Digestive Diseases and Sciences</i> , 1993 , 38, 916-22	4	59
45	Thyroid involvement in chronic inflammatory rheumatological disorders. <i>Clinical Rheumatology</i> , 1993 , 12, 479-84	3.9	30
44	Hepatic conversion of amino nitrogen to urea nitrogen in hypothyroid patients and upon L-thyroxine therapy. <i>Metabolism: Clinical and Experimental</i> , 1993 , 42, 1263-9	12.7	15
43	Effect of S-adenosyl-L-methionine administration on plasma levels of sulphur-containing amino acids in patients with liver cirrhosis. <i>Clinical Nutrition</i> , 1992 , 11, 303-8	5.9	13
42	Polyamine plasma levels and liver regeneration following partial hepatic resection in man. <i>Journal of Hepatology</i> , 1992 , 16, 159-64	13.4	8
41	Defective methionine metabolism in cirrhosis: relation to severity of liver disease. <i>Hepatology</i> , 1992 , 16, 149-55	11.2	53
40	Thyroid gland size and function in patients with cirrhosis of the liver. <i>Liver</i> , 1991 , 11, 71-7		17

39	Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score. <i>Digestive Diseases and Sciences</i> , 1991 , 36, 1197-203	4	72
38	Hepatic amino-nitrogen clearance to urea-nitrogen in control subjects and in patients with cirrhosis: A simplified method. <i>Hepatology</i> , 1991 , 13, 460-466	11.2	29
37	Intérêt de l'administration par voie orale d'acides aminés à chaîne ramifiée chez le cirrhotique encephalopathe chronique. <i>Nutrition Clinique Et Metabolisme</i> , 1991 , 5, 207-214	0.8	2
36	Oral BCAA in the treatment of chronic hepatic encephalopathy. <i>Journal of Hepatology</i> , 1991 , 12, 267	13.4	6
35	Elimination of infused branched-chain amino-acids from plasma of patients with non-obese type 2 diabetes mellitus. <i>Clinical Nutrition</i> , 1991 , 10, 105-13	5.9	11
34	Analysis of the deterioration rates of liver function in cirrhosis, based on galactose elimination capacity. <i>Liver</i> , 1990 , 10, 65-71		15
33	Glucose disposal, beta-cell secretion, and hepatic insulin extraction in cirrhosis: a minimal model assessment. <i>Gastroenterology</i> , 1990 , 99, 1715-22	13.3	65
32	Mathematical model to analyse urea synthesis following alanine infusion in control subjects and in patients with liver cirrhosis. <i>Medical and Biological Engineering and Computing</i> , 1990 , 28, 325-8	3.1	1
31	Ultrasonographic follow-up of liver cirrhosis. <i>Journal of Clinical Ultrasound</i> , 1990 , 18, 91-6	1	22
30	Synthesis of urea after a protein-rich meal in normal man in relation to ageing. <i>Age and Ageing</i> , 1990 , 19, 4-10	3	17
29	Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. <i>Journal of Hepatology</i> , 1990 , 11, 92-101	13.4	168
28	A rapid method for the in vivo measurement of liver volume. <i>Liver</i> , 1989 , 9, 159-63		25
27	Carbohydrate metabolism in hepatocellular carcinoma: where does the glucose go?. <i>Hepatology</i> , 1989 , 10, 253-5	11.2	7
26	Caffeine intake, fasting plasma caffeine and caffeine clearance in patients with liver diseases. <i>Liver</i> , 1988 , 8, 241-6		9
25	Galactose elimination capacity and liver volume in aging man. <i>Hepatology</i> , 1988 , 8, 1079-83	11.2	126
24	Insulin resistance in aged man: relationship between impaired glucose tolerance and decreased insulin activity on branched-chain amino acids. <i>Metabolism: Clinical and Experimental</i> , 1987 , 36, 1096-100	12.7	15
23	Plasma clearances of branched-chain amino acids in control subjects and in patients with cirrhosis. <i>Journal of Hepatology</i> , 1987 , 4, 108-17	13.4	48
22	Insulin resistance is the main determinant of impaired glucose tolerance in patients with liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1987 , 32, 1118-24	4	18

21	Evaluation of liver volume and liver function following hepatic resection in man. <i>Liver</i> , 1986 , 6, 286-91		32
20	Echo-Doppler measurement of splanchnic blood flow in control and cirrhotic subjects. <i>Journal of Clinical Ultrasound</i> , 1986 , 14, 429-35	1	100
19	Portal venous flow in response to acute beta-blocker and vasodilatory treatment in patients with liver cirrhosis. <i>Hepatology</i> , 1986 , 6, 1248-51	11.2	69
18	Sonographic evaluation of liver, spleen, and splanchnic vessels following partial liver resection. <i>Journal of Ultrasound in Medicine</i> , 1986 , 5, 563-7	2.9	3
17	Splanchnic vein measurements in patients with liver cirrhosis: a case-control study. <i>Journal of Ultrasound in Medicine</i> , 1985 , 4, 641-6	2.9	23
16	Degeneration of the corticospinal tract following portosystemic shunt associated with spinal cord infarction. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1985 , 406, 475-81		13
15	Portal pressure changes induced by medical treatment: US detection. <i>Radiology</i> , 1985 , 155, 763-6	20.5	13
14	Pancreatic beta-cell function in cirrhotic patients with and without overt diabetes. C-peptide response to glucagon and to meal. <i>Metabolism: Clinical and Experimental</i> , 1985 , 34, 695-701	12.7	22
13	The euglycemic clamp technique in patients with liver cirrhosis. <i>Hormone and Metabolic Research</i> , 1984 , 16, 341-3	3.1	18
12	Insulin-dependent metabolism of branched-chain amino acids in obesity. <i>Metabolism: Clinical and Experimental</i> , 1984 , 33, 147-50	12.7	46
11	Effect of euglycemic insulin infusion on plasma levels of branched-chain amino acids in cirrhosis. <i>Hepatology</i> , 1983 , 3, 184-7	11.2	29
10	Plasma amino acid response to protein ingestion in patients with liver cirrhosis. <i>Gastroenterology</i> , 1983 , 85, 283-290	13.3	32
9	Anticatabolic effect of branched-chain amino acid-enriched solutions in patients with liver cirrhosis. <i>Hepatology</i> , 1982 , 2, 420-5	11.2	73
8	Ammonia-induced changes in pancreatic hormones and plasma amino acids in patients with liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1982 , 27, 406-12	4	15
7	Muscle protein breakdown in uncontrolled diabetes as assessed by urinary 3-methylhistidine excretion. <i>Diabetologia</i> , 1982 , 23, 456-8	10.3	18
6	Branched-chain amino acids and alanine as indices of the metabolic control in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. <i>Diabetologia</i> , 1982 , 22, 217-9	10.3	37
5	Plasma amino acids as markers of liver dysfunction in cirrhotics. <i>Scandinavian Journal of Gastroenterology</i> , 1981 , 16, 689-92	2.4	10
4	Muscle protein breakdown in liver cirrhosis and the role of altered carbohydrate metabolism. <i>Hepatology</i> , 1981 , 1, 294-9	11.2	82

3	Prevalence of subclinical hepatic encephalopathy in cirrhotics and relationship to plasma amino acid imbalance. <i>Digestive Diseases and Sciences</i> , 1980 , 25, 763-8	4	50
2	Insulin and glucagon levels in liver cirrhosis. Relationship with plasma amino acid imbalance of chronic hepatic encephalopathy. <i>Digestive Diseases and Sciences</i> , 1979 , 24, 594-601	4	68
1	Nash As Part of the Metabolic (Insulin Resistance) Syndrome	55-65	1